# Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants

> **NCT06169085** · PHASE1 · COMPLETED · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 32 (actual)

## Conditions studied

- Elder

## Interventions

- **DRUG:** Leritrelvir

## Key facts

- **NCT ID:** NCT06169085
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-24
- **Primary completion:** 2023-09-20
- **Final completion:** 2023-10-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06169085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06169085, "Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06169085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*